Clinical Trials Logo
  1. Home
  2. Minimal Change Disease
  3. NCT06405100

Efficacy and Safety of Tacrolimus in Combination With Ripertamab in the Initial Treatment of Patients With MCD

Minimal Change Disease Clinical Trial

Official title:
Efficacy and Safety of Tacrolimus in Combination With Anti-CD20 Monoclonal Antibody (Ripertamab) in the Initial Treatment of Patients With Minimal Change Disease: a Multi-center Randomized Controlled Clinical Trial

Clinical Trial Summary

To evaluate the safety and efficacy of ripertamab and its combination with tacrolimus in the initial treatment of MCD to provide a treatment regimen with higher remission rates, lower recurrence rates, and fewer side effects in patients with MCD.

Clinical Trial Description

Minimal change disease is the third most common primary kidney disease in adults with idiopathic nephrotic syndrome. The pathological features of the disease are no or only slight changes under light microscope, and the foot process fusion under electron microscope. The KDIGO guidelines recommend oral adequate doses of glucocorticoids as the initial treatment for adults with MCD. However, 48%-76% of patients relapse after tapering or gradual discontinuation of the drug, requiring a high cumulative dose of glucocorticoids. As the cumulative dose of glucocorticoids increases, the potential for side effects increases. In addition, 10% to 30% of patients frequently relapse, and 15% to 30% of these are steroid dependent. Therefore, the clinical goals for patients with MCD are to achieve early remission of proteinuria, reduce hormonal side effects, and more importantly, prevent the recurrence of proteinuria. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT06405100
Study type Interventional
Source Air Force Military Medical University, China
Contact shiren Sun[Author], Doctor
Phone 18729387675
Email 272844142@qq.com
Status Not yet recruiting
Phase Phase 3
Start date May 2024
Completion date April 2027
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT05588063 - taVNS for FRNS in Children N/A
Recruiting NCT05583942 - A Pilot Trial of taVNS for SRNS in Children (kidNEY-VNS) N/A
Completed NCT04369183 - Rituximab for Refractory or Relapsed Focal Segmental Glomerulosclerosis or Minimal Change Disease
Recruiting NCT02896270 - Valproic Acid for Idiopathic Nephrotic Syndrome Phase 2/Phase 3
Completed NCT04009668 - Tumor Necrosis Factor Inhibition in Focal Segmental Glomerulosclerosis and Treatment Resistant Minimal Change Disease Phase 2
Terminated NCT05441826 - Efficacy and Safety of VB119 in Subjects With Minimal Change Disease (MCD) and Focal Segmental Glomerulosclerosis (FSGS) Phase 2
Recruiting NCT03929887 - KOrea Renal Biobank NEtwoRk System TOward NExt-generation Analysis
Active, not recruiting NCT03210688 - Active Vitamin D And Reduced Dose Prednisolone for Treatment in Minimal Change Nephropathy Phase 4
Completed NCT02592798 - Pilot Study to Evaluate the Safety and Efficacy of Abatacept in Adults and Children 6 Years and Older With Excessive Loss of Protein in the Urine Due to Either Focal Segmental Glomerulosclerosis (FSGS) or Minimal Change Disease (MCD) Phase 2
Enrolling by invitation NCT04571658 - NEPTUNE Match Study
Completed NCT01084980 - Therapeutic Effect of Tacrolimus in Combination With Low Dose Corticosteroid in Adult Patient With Minimal Change Nephritic Syndrome Phase 2/Phase 3
Recruiting NCT03068572 - Diagnostic Value of Linked Color Imaging for Minimal Change Esophagitis in Nonerosive Reflux Esophagitis and GERD N/A
Recruiting NCT05650619 - Recurrence Post-transplant Observational Study in Focal Segmental Glomerulosclerosis and Minimal Change Disease
Completed NCT00982072 - Tacrolimus Versus Prednisolone for the Treatment of Minimal Change Disease Phase 4
Terminated NCT04235621 - A Study to Understand the Genetics and Clinical Course of Focal Segmental Glomerulosclerosis (FSGS), Treatment-Resistant Minimal Change Disease (TR-MCD), and Diabetic Nephropathy (DN)
Recruiting NCT03298698 - Efficacy of Rituximab in Comparison to Continued Corticosteroid Treatment in Idiopathic Nephrotic Syndrome Phase 3
Recruiting NCT05003986 - Study of Sparsentan Treatment in Pediatrics With Proteinuric Glomerular Diseases Phase 2
Recruiting NCT05505500 - Interview Study of Adult and Child Patients and Parents of Children With Swelling Due to Nephrotic Syndrome.
Not yet recruiting NCT06315504 - Circulating Factors in Nephrotic Syndrome
Recruiting NCT03949972 - The FOrMe Registry (The German Focal Segmental Glomerulosclerosis and Minimal Change Disease Registry)